SynthesisJournal of neural transmission (Vienna, Austria : 1996)2008
Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review.
Synthesis in Journal of neural transmission (Vienna, Austria : 1996), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.The international journal of neuropsychopharmacology · 2015Trial
- Mapping thalamocortical functional connectivity with large-scale brain networks in patients with first-episode psychosis.Scientific reports · 2021Article
- Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study.European archives of psychiatry and clinical neuroscience · 2021Article
- The Contribution of Thalamic Nuclei in Salience Processing.Frontiers in behavioral neuroscience · 2021Review
- Rostral Intralaminar Thalamus Engagement in Cognition and Behavior.Frontiers in behavioral neuroscience · 2021Review
- In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.JAMA psychiatry · 2019Article
- A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway.Brain sciences · 2017Review
- Neuronal correlates of ketamine and walking induced gamma oscillations in the medial prefrontal cortex and mediodorsal thalamus.PloS one · 2017Article
- Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population.Scientific reports · 2016Article
- Altered Thalamo-Cortical White Matter Connectivity: Probabilistic Tractography Study in Clinical-High Risk for Psychosis and First-Episode Psychosis.Schizophrenia bulletin · 2016Article
- Identification of developmentally regulated PCP-responsive non-coding RNA, prt6, in the rat thalamus.PloS one · 2014Article
- Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function.Brain research · 2012Article
- An ICA with reference approach in identification of genetic variation and associated brain networks.Frontiers in human neuroscience · 2012Article
- Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia.Translational psychiatry · 2011Article
- Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.Biological psychiatry · 2011Article
- Dopamine neurons in the ventral tegmental area: an autopsy case of disorganized type of schizophrenia.Case reports in neurological medicine · 2011Article
- Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia.Schizophrenia bulletin · 2010Article
- Increased sensitivity to kainic acid in a genetic model of reduced NMDA receptor function.Brain research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thalamus, a key information processing centre in facilitating sensory discrimination and cognitive processes, has been implicated in schizophrenia due to the increasing evidence showing structural and functional thalamic abnormalities. Glutamatergic abnormalities, in particular, have been examined since glutamate is one of the main neurotransmitters found in the thalamus. We aimed to review the existing literature (1978 till 2007) on post-mortem and in vivo studies of the various components of glutamatergic neurotransmission as well as studies of the glutamate receptor genes within the thalamus in schizophrenia. The literature search was done using multiple databases including Scopus, Web of Science, EBSCO host, Pubmed and ScienceDirect. Keywords used were "glutamate", "thalamus", "schizophrenia", "abnormalities", and "glutamatergic". Further searches were made using the bibliographies in the main journals and related papers were obtained. The extant data suggest that abnormalities of the glutamate receptors as well as other molecules involved in glutamatergic neurotransmission (including glutamate transporters and associated proteins, N-methyl D-aspartate (NMDA) receptor-associated intracellular signaling proteins, and glutamatergic enzymes) are found within the thalamus in schizophrenia. There is a pressing need for more rapid replication of findings from post mortem and genetic studies as well as the promotion of multi-component or multi-modality assessments of glutamatergic anomalies within the thalamus in order to allow a better appreciation of disruptions in these molecular networks in schizophrenia. These and future findings may represent potential novel targets for antipsychotic drugs to ameliorate the symptoms of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.